DGAP-News

Medios AG starts the 2021 financial year with a record quarter - Seite 2

The latest acquisitions have increased Medios' partner network to around 500 specialized pharmacies.

The United Nations Global Compact is the world's largest initiative for responsible corporate leadership. By joining in the first quarter of 2021, Medios has committed to upholding the network's ten universal principles and sustainability goals. Medios' aim is to adopt a comprehensive ESG strategy in the 2021 financial year. The company's ESG activities are explained for the first time in a voluntary Nonfinancial Group Statement in the Annual Report 2020.

With the innovative mediosconnect software platform, the company is already well prepared for the introduction of the legally required e-prescription on January 1, 2022. This digital platform for complex and individualized medicines connects doctors, health insurers and specialized pharmacies and automates ordering and billing processes. The platform is so far online in Berlin and Mecklenburg-Western Pomerania and will be rolled out in other federal states.

As part of its strategy to expand the higher-margin business segment of Patient-Specific Therapies, Medios began setting up additional laboratories at the beginning of the reporting year. With the completion of the most modern and GMP-certified laboratories at the end of 2021, it will be possible to triple manufacturing capacities.

Positive outlook for 2021 confirmed
Medios expects strong growth in the 2021 financial year despite the still challenging market environment. The company expects group sales of €1.15 to 1.20 billion, EBITDA pre¹ of €38 to 39 million and EBT pre¹ of €31 to 32 million. This corresponds to a group sales increase of around 84 to 92% as well as an even more significant growth in EBITDA pre¹ of around 152 to 159% and an increase in EBT pre¹ of around 158 to 166%.

Key financials (IFRS)
in € million		Q1 2021		Q1 2020		∆ in %
Group sales		315.9		162.8		94.0
Pharmaceutical Supply		299.6		148.2		>100
Patient-Specific Therapies		16.1		14.5		11.0
Services		0.1		0.1		90.9
EBITDA pre1		8.8		4.3		>100
Pharmaceutical Supply		7.0		2.3		>100
Patient-Specific Therapies		2.2		1.8		20.2
Services		-0.4		0.1		<-100
EBT pre1		7.1		3.7		90.7
Pharmaceutical Supply		5.7		2.0		>100
Patient-Specific Therapies		1.9		1.6		18.8
Services		-0.6		0.1		<-100
Cashflow from operating activities		21.4		-10.5		<-100

 

The Quarterly Statement as of March 31, 2021 is available for download on the Investor Relations website https://medios.ag/en/investor-relations/reporting-center.